1. Home
  2. DCBO vs VNDA Comparison

DCBO vs VNDA Comparison

Compare DCBO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Docebo Inc.

DCBO

Docebo Inc.

HOLD

Current Price

$15.68

Market Cap

489.9M

Sector

N/A

ML Signal

HOLD

Logo Vanda Pharmaceuticals Inc.

VNDA

Vanda Pharmaceuticals Inc.

HOLD

Current Price

$7.31

Market Cap

474.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCBO
VNDA
Founded
2016
2002
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
489.9M
474.0M
IPO Year
2020
2005

Fundamental Metrics

Financial Performance
Metric
DCBO
VNDA
Price
$15.68
$7.31
Analyst Decision
Buy
Strong Buy
Analyst Count
9
5
Target Price
$32.00
$14.90
AVG Volume (30 Days)
101.5K
1.5M
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$216,105,000.00
Revenue This Year
$12.89
$21.35
Revenue Next Year
$11.44
$37.40
P/E Ratio
$22.04
N/A
Revenue Growth
N/A
8.72
52 Week Low
$14.39
$3.81
52 Week High
$33.69
$9.91

Technical Indicators

Market Signals
Indicator
DCBO
VNDA
Relative Strength Index (RSI) 36.99 47.26
Support Level N/A $7.12
Resistance Level $20.15 $8.29
Average True Range (ATR) 0.87 0.33
MACD -0.25 0.02
Stochastic Oscillator 25.73 58.20

Price Performance

Historical Comparison
DCBO
VNDA

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Share on Social Networks: